Antiestrogens: structure-activity relationships and use in breast cancer treatment - Test2 - elhamkhani - TriplyDB

Antiestrogens: structure-activity relationships and use in breast cancer treatment

Antiestrogens: structure-activity relationships and use in breast cancer treatment

http://www.wikidata.org/entity/Q28077245

about

The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Anticancer Activities of C18-, C19-, C20-, and Bis-Diterpenoid Alkaloids Derived from Genus Aconitum.Steroidal Pyrimidines and Dihydrotriazines as Novel Classes of Anticancer Agents against Hormone-Dependent Breast Cancer Cells.Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity.Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect Efficacy of tamoxifen for the treatment of severe equine asthma

P2860

Q33809605-FF42962F-618B-4192-AAA7-FA030DD44D67 Q39139318-71984DF5-05F5-494F-8561-B02ED740AE9C Q49268662-557EA592-B6EE-4717-A4AA-087D6C4FAD79 Q55242399-2F06C18D-14A3-4410-849E-4692B4113E7C Q56648554-0A67BEE6-821F-449E-8DF3-8C75EB2FFBBD Q58796490-C864E609-5CC3-4CE0-AF5D-EFB28F811F40

P2860

Antiestrogens: structure-activity relationships and use in breast cancer treatment

http://www.wikidata.org/entity/Q28077245

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@ast

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@en

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@nl

type

label

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@ast

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@en

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@nl

prefLabel

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@ast

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@en

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@nl

P1433

Q28077245-CE9C3653-FA48-4741-8E85-313508358214

P1476

Q28077245-5CFBE105-34CC-4E62-A2F8-C919B49BC686

P2093

Q28077245-52A989F0-28BF-46AC-9F0D-9219CF099E61

Q28077245-8D579842-F31C-49C4-8A85-D7337782DF6E

Q28077245-EE7C201F-7908-4D18-BCAF-2D58245C323E

Q28077245-FA376F13-B46A-450C-913E-D7F71769C2AD

P275

Q28077245-DF256ED7-B13F-4690-83A2-60160B07E3D5

P2860

Q28077245-00FEFEA9-D70F-4E72-916E-D57BD0D50311

Q28077245-03D08FA4-3141-4797-BBBD-9BD6D7F9092F

Q28077245-0468F8EA-246B-4DD6-9CF4-1D0EEB5F0BAB

Q28077245-07B2BF01-7343-4CF3-8311-1155723CE7E8

Q28077245-0CA5CF54-4866-4BA0-A253-94959E8CC00C

Q28077245-0CC2F7B3-C9BA-4598-A977-881F2A360530

Q28077245-10666363-6BED-43B7-8C6A-964DE7908239

Q28077245-1292709A-AEA3-48E8-8865-AAB786203945

Q28077245-12C1E37F-4DDD-4CE0-B288-DEBC25283F6B

Q28077245-14F79606-8E4C-4E9E-BF34-F94A8782EBE5

P304

Q28077245-DD8175F8-1E2D-4EC9-9752-CACB0EF826E6

P31

Q28077245-7CD023B4-7806-4B4A-B904-B0026B6111FC

Q28077245-A3C5E504-D940-4FC0-B629-1613E07ACBAC

P356

Q28077245-A92EC32B-9167-43C4-9714-EE14A8538BB4

P407

Q28077245-65C57C7B-5ACB-41B3-9C39-1EDBA8A607AD

P433

Q28077245-6BE5463A-B415-4297-87D8-30480A921A6B

P478

Q28077245-6352B090-BA98-476A-A318-BF9C7E6152D6

P577

Q28077245-12535C7C-02F4-44C2-B0B4-541E2A266FDF

Q28077245-917B6CEF-6355-4AE0-8795-12A31A5C31D0

P698

Q28077245-1515FAC5-409D-4742-A6FC-0369E7A02C48

P921

Q28077245-5AA48CC5-6DFD-436B-B04B-410C7CD8257E

P932

Q28077245-383781B0-040F-4947-8B2F-2EB70703A1C4

P356

P1433

Journal of Molecular Endocrinology

P1476

Antiestrogens: structure-activity relationships and use in breast cancer treatment

@en

P2093

James Gleason

http://www.w3.org/2001/XMLSchema#string

Mohamed El Ezzy

http://www.w3.org/2001/XMLSchema#string

Sylvie Mader

http://www.w3.org/2001/XMLSchema#string

Tatiana Traboulsi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex

Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2.

Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Estrogen receptors and human disease

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

Structural insights into the mode of action of a pure antiestrogen

Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha

Structural insights into corepressor recognition by antagonist-bound estrogen receptors

NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses

P304

R15-R31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/JME-16-0024

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27729460

http://www.w3.org/2001/XMLSchema#string

P921

hormone antagonist

P932

5148801

http://www.w3.org/2001/XMLSchema#string